drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00773 | DB01610 | 896 | 248 | [
"DDInter702",
"DDInter1912"
] | Etoposide | Valganciclovir | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
896,
24,
248
]
],
[
[
896,
24,
563
],
[
563,
1,
248
]
],
[
[
896,
21,
29209
],
[
29209,
60,
248
]
],
[
[
896,
63,
1101
],
[
1101,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Etoposide (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Etoposide may cause a moderate interac... |
DB00317 | DB00476 | 883 | 109 | [
"DDInter810",
"DDInter608"
] | Gefitinib | Duloxetine | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
883,
24,
109
]
],
[
[
883,
63,
847
],
[
847,
1,
109
]
],
[
[
883,
6,
12523
],
[
12523,
45,
109
]
],
[
[
883,
21,
28864
],
[
28864,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Duloxetine (Compound)
Gefitinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Duloxetine (Compound)
Gefitinib (Compound) causes Erythema multiforme (Side Effect) and ... |
DB00220 | DB12364 | 798 | 1,421 | [
"DDInter1276",
"DDInter200"
] | Nelfinavir | Betrixaban | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
798,
25,
1421
]
],
[
[
798,
25,
1017
],
[
1017,
24,
1421
]
],
[
[
798,
24,
1151
],
[
1151,
24,
1421
]
],
[
[
798,
23,
222
],
[
222,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} m... | Nelfinavir may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a ... |
DB09030 | DB09280 | 840 | 1,604 | [
"DDInter1945",
"DDInter1101"
] | Vorapaxar | Lumacaftor | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
840,
25,
1604
]
],
[
[
840,
64,
1171
],
[
1171,
24,
1604
]
],
[
[
840,
63,
1061
],
[
1061,
24,
1604
]
],
[
[
840,
24,
1427
],
[
1427,
... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meloxicam"
],
[
"Meloxicam",
"{u} may c... | Vorapaxar may lead to a major life threatening interaction when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause ... |
DB01042 | DB15091 | 1,307 | 676 | [
"DDInter1144",
"DDInter1901"
] | Melphalan | Upadacitinib | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1307,
25,
676
]
],
[
[
1307,
23,
1193
],
[
1193,
23,
676
]
],
[
[
1307,
63,
1461
],
[
1461,
23,
676
]
],
[
[
1307,
24,
1430
],
[
1430,... | [
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Melphalan may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vit... |
DB00877 | DB09054 | 629 | 384 | [
"DDInter1678",
"DDInter905"
] | Sirolimus | Idelalisib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
629,
25,
384
]
],
[
[
629,
24,
222
],
[
222,
23,
384
]
],
[
[
629,
63,
1230
],
[
1230,
23,
384
]
],
[
[
629,
24,
1627
],
[
1627,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopr... |
DB09156 | DB14509 | 777 | 1,399 | [
"DDInter964",
"DDInter1081"
] | Iopromide | Lithium carbonate | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Major | 2 | [
[
[
777,
25,
1399
]
],
[
[
777,
64,
589
],
[
589,
23,
1399
]
],
[
[
777,
63,
1574
],
[
1574,
23,
1399
]
],
[
[
777,
64,
387
],
[
387,
... | [
[
[
"Iopromide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iopromide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u... | Iopromide may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a minor int... |
DB00445 | DB00889 | 322 | 1,133 | [
"DDInter655",
"DDInter840"
] | Epirubicin | Granisetron | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
322,
24,
1133
]
],
[
[
322,
7,
2652
],
[
2652,
46,
1133
]
],
[
[
322,
18,
8386
],
[
8386,
57,
1133
]
],
[
[
322,
21,
29282
],
[
29282,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"CASP10"
],
[
"CASP10",
"{u} (Gene) is upregulated by {v}... | Epirubicin (Compound) upregulates CASP10 (Gene) and CASP10 (Gene) is upregulated by Granisetron (Compound)
Epirubicin (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Granisetron (Compound)
Epirubicin (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Granis... |
DB00404 | DB00434 | 523 | 13 | [
"DDInter54",
"DDInter459"
] | Alprazolam | Cyproheptadine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
523,
24,
13
]
],
[
[
523,
24,
104
],
[
104,
63,
13
]
],
[
[
523,
18,
2942
],
[
2942,
46,
13
]
],
[
[
523,
7,
2969
],
[
2969,
46,... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Alprazolam (Compound) downregulates KEAP1 (Gene) and KEAP1 (Gene) is upregulated by Cyproheptadine (Comp... |
DB01390 | DB11751 | 1,117 | 1,239 | [
"DDInter1683",
"DDInter261"
] | Sodium bicarbonate | Cabotegravir | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine].[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir], which resulted in the development of long acting m... | Moderate | 1 | [
[
[
1117,
24,
1239
]
],
[
[
1117,
62,
664
],
[
664,
23,
460
],
[
460,
24,
1239
]
],
[
[
1117,
23,
1468
],
[
1468,
23,
460
],
[
460,
24,
... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabotegravir"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perindopril... | Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when take... |
DB01142 | DB01267 | 1,264 | 519 | [
"DDInter593",
"DDInter1381"
] | Doxepin | Paliperidone | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
1264,
24,
519
]
],
[
[
1264,
63,
1664
],
[
1664,
1,
519
]
],
[
[
1264,
25,
924
],
[
924,
1,
519
]
],
[
[
1264,
6,
2250
],
[
2250,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Doxepin may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Doxepin (Comp... |
DB00359 | DB08870 | 161 | 850 | [
"DDInter1721",
"DDInter228"
] | Sulfadiazine | Brentuximab vedotin | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
161,
24,
850
]
],
[
[
161,
24,
267
],
[
267,
24,
850
]
],
[
[
161,
63,
245
],
[
245,
24,
850
]
],
[
[
161,
1,
50
],
[
50,
24,
... | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepir... |
DB00056 | DB08904 | 816 | 375 | [
"DDInter814",
"DDInter342"
] | Gemtuzumab ozogamicin | Certolizumab pegol | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
816,
25,
375
]
],
[
[
816,
24,
200
],
[
200,
63,
375
]
],
[
[
816,
24,
66
],
[
66,
24,
375
]
],
[
[
816,
25,
1066
],
[
1066,
25,... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albi... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate dise... |
DB00014 | DB01001 | 521 | 688 | [
"DDInter839",
"DDInter1632"
] | Goserelin | Salbutamol | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
521,
24,
688
]
],
[
[
521,
24,
455
],
[
455,
24,
688
]
],
[
[
521,
24,
1148
],
[
1148,
63,
688
]
],
[
[
521,
21,
28714
],
[
28714,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isopre... |
DB06414 | DB12267 | 655 | 1,476 | [
"DDInter703",
"DDInter233"
] | Etravirine | Brigatinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
655,
25,
1476
]
],
[
[
655,
24,
1135
],
[
1135,
23,
1476
]
],
[
[
655,
62,
168
],
[
168,
23,
1476
]
],
[
[
655,
63,
629
],
[
629,
... | [
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Etravirine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib m... |
DB00582 | DB11979 | 1,622 | 1,320 | [
"DDInter1946",
"DDInter625"
] | Voriconazole | Elagolix | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
1622,
25,
1320
]
],
[
[
1622,
63,
168
],
[
168,
23,
1320
]
],
[
[
1622,
25,
1297
],
[
1297,
24,
1320
]
],
[
[
1622,
63,
79
],
[
79,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezom... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Voriconazole may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may ca... |
DB00367 | DB08899 | 566 | 129 | [
"DDInter1061",
"DDInter649"
] | Levonorgestrel | Enzalutamide | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
566,
24,
129
]
],
[
[
566,
6,
8374
],
[
8374,
45,
129
]
],
[
[
566,
21,
29377
],
[
29377,
60,
129
]
],
[
[
566,
24,
1510
],
[
1510,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (C... | Levonorgestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Levonorgestrel (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Levonorgestrel may cause a moderate interaction that could exacerbate diseas... |
DB01105 | DB01225 | 222 | 500 | [
"DDInter1665",
"DDInter645"
] | Sibutramine | Enoxaparin | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
222,
24,
500
]
],
[
[
222,
21,
29173
],
[
29173,
60,
500
]
],
[
[
222,
64,
1230
],
[
1230,
24,
500
]
],
[
[
222,
25,
1039
],
[
1039,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Sibutramine",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema peripheral"
],
[
"Oedema peripheral",
"{u} (Si... | Sibutramine (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Enoxaparin (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Enox... |
DB00295 | DB00765 | 475 | 1,266 | [
"DDInter1244",
"DDInter1205"
] | Morphine | Metyrosine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Moderate | 1 | [
[
[
475,
24,
1266
]
],
[
[
475,
21,
28779
],
[
28779,
60,
1266
]
],
[
[
475,
24,
662
],
[
662,
24,
1266
]
],
[
[
475,
24,
401
],
[
401,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrosine"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused b... | Morphine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Metyrosine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metyr... |
DB00073 | DB05273 | 1,394 | 507 | [
"DDInter1608",
"DDInter1638"
] | Rituximab | Samarium (153Sm) lexidronam | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
1394,
25,
507
]
],
[
[
1394,
24,
248
],
[
248,
24,
507
]
],
[
[
1394,
24,
270
],
[
270,
63,
507
]
],
[
[
1394,
25,
1064
],
[
1064,
... | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Rituximab may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01390 | DB11613 | 1,117 | 1,519 | [
"DDInter1683",
"DDInter1924"
] | Sodium bicarbonate | Velpatasvir | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
1117,
24,
1519
]
],
[
[
1117,
24,
594
],
[
594,
24,
1519
]
],
[
[
1117,
62,
1559
],
[
1559,
24,
1519
]
],
[
[
1117,
24,
1040
],
[
1040... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"... | Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Famotidi... |
DB00468 | DB01118 | 1,424 | 33 | [
"DDInter1557",
"DDInter76"
] | Quinine | Amiodarone | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Major | 2 | [
[
[
1424,
25,
33
]
],
[
[
1424,
25,
540
],
[
540,
1,
33
]
],
[
[
1424,
24,
1120
],
[
1120,
1,
33
]
],
[
[
1424,
6,
7950
],
[
7950,
4... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Comp... | Quinine may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Proparacaine and Proparacaine (Compound) resembles Amiodarone (Compound)
Quinine (Compou... |
DB00186 | DB00281 | 905 | 608 | [
"DDInter1092",
"DDInter1066"
] | Lorazepam | Lidocaine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anes... | Moderate | 1 | [
[
[
905,
24,
608
]
],
[
[
905,
21,
28722
],
[
28722,
60,
608
]
],
[
[
905,
24,
1017
],
[
1017,
62,
608
]
],
[
[
905,
40,
1119
],
[
1119,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Lorazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v}... | Lorazepam (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound)
Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Lorazepa... |
DB00402 | DB00470 | 1,407 | 530 | [
"DDInter685",
"DDInter601"
] | Eszopiclone | Dronabinol | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
1407,
24,
530
]
],
[
[
1407,
24,
1614
],
[
1614,
40,
530
]
],
[
[
1407,
6,
6017
],
[
6017,
45,
530
]
],
[
[
1407,
21,
28708
],
[
28708... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Eszopiclone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dronabinol (Compound)
Eszopiclone (Compound) causes Malaise (Side Effect) and Malaise (Sid... |
DB00361 | DB06186 | 134 | 1,439 | [
"DDInter1939",
"DDInter969"
] | Vinorelbine | Ipilimumab | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
134,
24,
1439
]
],
[
[
134,
24,
1060
],
[
1060,
63,
1439
]
],
[
[
134,
63,
482
],
[
482,
24,
1439
]
],
[
[
134,
24,
671
],
[
671,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Tio... |
DB00514 | DB15982 | 506 | 1,339 | [
"DDInter527",
"DDInter193"
] | Dextromethorphan | Berotralstat | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
506,
24,
1339
]
],
[
[
506,
25,
222
],
[
222,
23,
1339
]
],
[
[
506,
24,
283
],
[
283,
23,
1339
]
],
[
[
506,
25,
1133
],
[
1133,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
... | Dextromethorphan may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedrati... |
DB00635 | DB00703 | 1,573 | 997 | [
"DDInter1515",
"DDInter1167"
] | Prednisone | Methazolamide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Moderate | 1 | [
[
[
1573,
24,
997
]
],
[
[
1573,
24,
471
],
[
471,
1,
997
]
],
[
[
1573,
6,
10215
],
[
10215,
45,
997
]
],
[
[
1573,
21,
28809
],
[
28809,... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound)
Prednisone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Methazolamide (Compound)
Prednisone (Compound) causes Diarrhoea (Side Effect)... |
DB00741 | DB08912 | 167 | 1,040 | [
"DDInter885",
"DDInter462"
] | Hydrocortisone | Dabrafenib | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
167,
24,
1040
]
],
[
[
167,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
167,
7,
3361
],
[
3361,
46,
1040
]
],
[
[
167,
18,
20113
],
[
20113,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compo... | Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Hydrocortisone (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Dabrafenib (Compound)
Hydrocortisone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Dabrafenib (Compound)
Hydroc... |
DB00261 | DB05294 | 702 | 1,069 | [
"DDInter93",
"DDInter1917"
] | Anagrelide | Vandetanib | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
702,
25,
1069
]
],
[
[
702,
7,
4351
],
[
4351,
45,
1069
]
],
[
[
702,
21,
29343
],
[
29343,
60,
1069
]
],
[
[
702,
23,
1247
],
[
1247,... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Anagrelide",
"{u} (Compound) upregulates {v} (Gene)",
"MKNK1"
],
[
"MKNK1",
"{u} (Gene) is bound by {v} (Compound)",
"Van... | Anagrelide (Compound) upregulates MKNK1 (Gene) and MKNK1 (Gene) is bound by Vandetanib (Compound)
Anagrelide (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects... |
DB00900 | DB09054 | 45 | 384 | [
"DDInter544",
"DDInter905"
] | Didanosine | Idelalisib | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
45,
24,
384
]
],
[
[
45,
24,
72
],
[
72,
24,
384
]
],
[
[
45,
63,
305
],
[
305,
24,
384
]
],
[
[
45,
64,
1101
],
[
1101,
24,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
... | Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escher... |
DB01403 | DB06663 | 9 | 1,154 | [
"DDInter1175",
"DDInter1398"
] | Methotrimeprazine | Pasireotide | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
9,
25,
1154
]
],
[
[
9,
21,
28898
],
[
28898,
60,
1154
]
],
[
[
9,
62,
112
],
[
112,
23,
1154
]
],
[
[
9,
24,
1385
],
[
1385,
63... | [
[
[
"Methotrimeprazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Methotrimeprazine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) i... | Methotrimeprazine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pasireotide (Compound)
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects ... |
DB01203 | DB09133 | 699 | 1,527 | [
"DDInter1255",
"DDInter965"
] | Nadolol | Iothalamic acid | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
699,
24,
1527
]
],
[
[
699,
24,
278
],
[
278,
63,
1527
]
],
[
[
699,
40,
887
],
[
887,
24,
1527
]
],
[
[
699,
24,
512
],
[
512,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
[
... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Nadolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could ... |
DB00719 | DB14881 | 1,219 | 180 | [
"DDInter149",
"DDInter1329"
] | Azatadine | Oliceridine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1219,
24,
180
]
],
[
[
1219,
24,
401
],
[
401,
24,
180
]
],
[
[
1219,
63,
85
],
[
85,
24,
180
]
],
[
[
1219,
40,
830
],
[
830,
2... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atrop... |
DB00502 | DB00748 | 1,300 | 662 | [
"DDInter853",
"DDInter297"
] | Haloperidol | Carbinoxamine | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
1300,
24,
662
]
],
[
[
1300,
24,
28
],
[
28,
40,
662
]
],
[
[
1300,
63,
1594
],
[
1594,
24,
662
]
],
[
[
1300,
40,
11407
],
[
11407,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that co... |
DB00841 | DB01261 | 532 | 170 | [
"DDInter577",
"DDInter1679"
] | Dobutamine | Sitagliptin | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
532,
24,
170
]
],
[
[
532,
21,
28762
],
[
28762,
60,
170
]
],
[
[
532,
24,
52
],
[
52,
62,
170
]
],
[
[
532,
63,
1179
],
[
1179,
... | [
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Dobutamine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cause... | Dobutamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Sitagliptin (Compound)
Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitaglip... |
DB00812 | DB06209 | 998 | 256 | [
"DDInter1451",
"DDInter1508"
] | Phenylbutazone | Prasugrel | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
998,
25,
256
]
],
[
[
998,
6,
8374
],
[
8374,
45,
256
]
],
[
[
998,
63,
888
],
[
888,
23,
256
]
],
[
[
998,
63,
305
],
[
305,
24... | [
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"... | Phenylbutazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Phenylbutazone m... |
DB00563 | DB00635 | 663 | 1,573 | [
"DDInter1174",
"DDInter1515"
] | Methotrexate | Prednisone | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
663,
24,
1573
]
],
[
[
663,
24,
175
],
[
175,
40,
1573
]
],
[
[
663,
63,
251
],
[
251,
1,
1573
]
],
[
[
663,
24,
167
],
[
167,
1... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Predni... |
DB00400 | DB08820 | 353 | 1,478 | [
"DDInter843",
"DDInter997"
] | Griseofulvin | Ivacaftor | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
353,
24,
1478
]
],
[
[
353,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
353,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
353,
24,
907
],
[
907,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Griseofulvin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Do... |
DB00962 | DB11130 | 1,639 | 407 | [
"DDInter1957",
"DDInter1344"
] | Zaleplon | Opium | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1639,
24,
407
]
],
[
[
1639,
63,
662
],
[
662,
24,
407
]
],
[
[
1639,
24,
849
],
[
849,
24,
407
]
],
[
[
1639,
64,
475
],
[
475,
... | [
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"C... | Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramin... |
DB00206 | DB11827 | 1,245 | 433 | [
"DDInter1582",
"DDInter669"
] | Reserpine | Ertugliflozin | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1245,
24,
433
]
],
[
[
1245,
24,
959
],
[
959,
24,
433
]
],
[
[
1245,
63,
73
],
[
73,
24,
433
]
],
[
[
1245,
24,
1019
],
[
1019,
... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phente... |
DB00761 | DB00835 | 1,621 | 100 | [
"DDInter1497",
"DDInter245"
] | Potassium chloride | Brompheniramine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Major | 2 | [
[
[
1621,
25,
100
]
],
[
[
1621,
25,
832
],
[
832,
24,
100
]
],
[
[
1621,
64,
508
],
[
508,
24,
100
]
],
[
[
1621,
25,
211
],
[
211,
... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brompheniramine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tripelennamine"
],
[
"... | Potassium chloride may lead to a major life threatening interaction when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Potassium chloride may lead to a major life threatening interaction when taken with Promazine and Promazin... |
DB00515 | DB14711 | 589 | 779 | [
"DDInter387",
"DDInter1680"
] | Cisplatin | Smallpox (Vaccinia) Vaccine, Live | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
589,
25,
779
]
],
[
[
589,
64,
1064
],
[
1064,
25,
779
]
],
[
[
589,
25,
1377
],
[
1377,
25,
779
]
],
[
[
589,
24,
147
],
[
147,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Clad... | Cisplatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Cisplatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a maj... |
DB00095 | DB11003 | 66 | 748 | [
"DDInter623",
"DDInter100"
] | Efalizumab | Anthrax vaccine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
66,
24,
748
]
],
[
[
66,
24,
322
],
[
322,
24,
748
]
],
[
[
66,
24,
564
],
[
564,
63,
748
]
],
[
[
66,
25,
676
],
[
676,
63,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and ... |
DB00261 | DB01240 | 702 | 885 | [
"DDInter93",
"DDInter657"
] | Anagrelide | Epoprostenol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
702,
24,
885
]
],
[
[
702,
24,
1061
],
[
1061,
1,
885
]
],
[
[
702,
21,
28684
],
[
28684,
60,
885
]
],
[
[
702,
23,
539
],
[
539,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Anagrelide (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Anagrelide may cause a minor... |
DB00912 | DB09098 | 473 | 98 | [
"DDInter1581",
"DDInter1700"
] | Repaglinide | Somatrem | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
473,
24,
98
]
],
[
[
473,
24,
1612
],
[
1612,
62,
98
]
],
[
[
473,
63,
168
],
[
168,
23,
98
]
],
[
[
473,
24,
336
],
[
336,
24,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortez... |
DB00242 | DB01181 | 1,064 | 1,532 | [
"DDInter392",
"DDInter906"
] | Cladribine | Ifosfamide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Major | 2 | [
[
[
1064,
25,
1532
]
],
[
[
1064,
5,
11555
],
[
11555,
44,
1532
]
],
[
[
1064,
21,
29209
],
[
29209,
60,
1532
]
],
[
[
1064,
64,
1648
],
[
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cladribine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated b... | Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Cladribine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound)
Cladribine may lead to a major life threatening interaction when taken with Ald... |
DB00247 | DB06589 | 1,131 | 1,250 | [
"DDInter1194",
"DDInter1400"
] | Methysergide | Pazopanib | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1131,
24,
1250
]
],
[
[
1131,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
1131,
40,
628
],
[
628,
24,
1250
]
],
[
[
1131,
24,
1419
],
[
14... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is cau... | Methysergide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Methysergide (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Methysergide may cause a moderate interact... |
DB00372 | DB01203 | 999 | 699 | [
"DDInter1793",
"DDInter1255"
] | Thiethylperazine | Nadolol | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
999,
24,
699
]
],
[
[
999,
24,
887
],
[
887,
1,
699
]
],
[
[
999,
62,
417
],
[
417,
23,
699
]
],
[
[
999,
23,
1283
],
[
1283,
62... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Nadolol (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can l... |
DB00496 | DB11730 | 194 | 351 | [
"DDInter480",
"DDInter1588"
] | Darifenacin | Ribociclib | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
194,
24,
351
]
],
[
[
194,
24,
283
],
[
283,
62,
351
]
],
[
[
194,
63,
597
],
[
597,
24,
351
]
],
[
[
194,
24,
98
],
[
98,
24,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and C... |
DB00238 | DB09073 | 188 | 951 | [
"DDInter1285",
"DDInter1379"
] | Nevirapine | Palbociclib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
188,
24,
951
]
],
[
[
188,
25,
1476
],
[
1476,
63,
951
]
],
[
[
188,
24,
1033
],
[
1033,
63,
951
]
],
[
[
188,
24,
467
],
[
467,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatini... | Nevirapine may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a... |
DB00790 | DB08880 | 664 | 1,510 | [
"DDInter1431",
"DDInter1771"
] | Perindopril | Teriflunomide | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
664,
25,
1510
]
],
[
[
664,
63,
1144
],
[
1144,
24,
1510
]
],
[
[
664,
24,
1450
],
[
1450,
63,
1510
]
],
[
[
664,
24,
170
],
[
170,
... | [
[
[
"Perindopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nate... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin ... |
DB00307 | DB01224 | 1,101 | 623 | [
"DDInter202",
"DDInter1553"
] | Bexarotene | Quetiapine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Major | 2 | [
[
[
1101,
25,
623
]
],
[
[
1101,
24,
827
],
[
827,
1,
623
]
],
[
[
1101,
23,
851
],
[
851,
1,
623
]
],
[
[
1101,
25,
695
],
[
695,
1... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quetiapine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
"Trazodone",... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compound)
Bexa... |
DB00095 | DB06772 | 66 | 310 | [
"DDInter623",
"DDInter259"
] | Efalizumab | Cabazitaxel | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
66,
24,
310
]
],
[
[
66,
24,
973
],
[
973,
24,
310
]
],
[
[
66,
24,
800
],
[
800,
63,
310
]
],
[
[
66,
63,
58
],
[
58,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duveli... |
DB00106 | DB01591 | 618 | 667 | [
"DDInter4",
"DDInter1696"
] | Abarelix | Solifenacin | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
618,
24,
667
]
],
[
[
618,
23,
112
],
[
112,
23,
667
]
],
[
[
618,
24,
392
],
[
392,
24,
667
]
],
[
[
618,
24,
1228
],
[
1228,
6... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Solifenacin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatini... |
DB08865 | DB14730 | 1,593 | 1,412 | [
"DDInter448",
"DDInter264"
] | Crizotinib | Calaspargase pegol | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1593,
24,
1412
]
],
[
[
1593,
63,
792
],
[
792,
24,
1412
]
],
[
[
1593,
24,
159
],
[
159,
24,
1412
]
],
[
[
1593,
64,
322
],
[
322,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectin... |
DB00726 | DB12332 | 1,164 | 1,619 | [
"DDInter1876",
"DDInter1626"
] | Trimipramine | Rucaparib | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1164,
24,
1619
]
],
[
[
1164,
25,
222
],
[
222,
23,
1619
]
],
[
[
1164,
23,
112
],
[
112,
23,
1619
]
],
[
[
1164,
24,
1662
],
[
1662,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutr... | Trimipramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may... |
DB00674 | DB01211 | 1,516 | 609 | [
"DDInter802",
"DDInter393"
] | Galantamine | Clarithromycin | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1516,
24,
609
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
609
]
],
[
[
1516,
21,
28759
],
[
28759,
60,
609
]
],
[
[
1516,
63,
600
],
[
600,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Galantamine (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Galantamine may cause a moderate interaction that could exacerbate... |
DB00962 | DB01246 | 1,639 | 820 | [
"DDInter1957",
"DDInter45"
] | Zaleplon | Alimemazine | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1639,
24,
820
]
],
[
[
1639,
24,
401
],
[
401,
24,
820
]
],
[
[
1639,
24,
649
],
[
649,
1,
820
]
],
[
[
1639,
6,
8374
],
[
8374,
... | [
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofe... |
DB00414 | DB14730 | 590 | 1,412 | [
"DDInter16",
"DDInter264"
] | Acetohexamide | Calaspargase pegol | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
590,
24,
1412
]
],
[
[
590,
24,
5
],
[
5,
24,
1412
]
],
[
[
590,
63,
1179
],
[
1179,
24,
1412
]
],
[
[
590,
64,
600
],
[
600,
24... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insul... |
DB00705 | DB11730 | 441 | 351 | [
"DDInter496",
"DDInter1588"
] | Delavirdine | Ribociclib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
441,
25,
351
]
],
[
[
441,
23,
466
],
[
466,
62,
351
]
],
[
[
441,
23,
222
],
[
222,
23,
351
]
],
[
[
441,
25,
283
],
[
283,
62,... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Delavirdine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibut... |
DB00620 | DB10315 | 175 | 1,137 | [
"DDInter1855",
"DDInter1127"
] | Triamcinolone | Measles virus vaccine live attenuated | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
175,
25,
1137
]
],
[
[
175,
1,
617
],
[
617,
24,
1137
]
],
[
[
175,
64,
581
],
[
581,
25,
1137
]
],
[
[
175,
25,
384
],
[
384,
2... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} m... | Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Triamcinolone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life ... |
DB00496 | DB04843 | 194 | 1,511 | [
"DDInter480",
"DDInter1149"
] | Darifenacin | Mepenzolate | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
194,
24,
1511
]
],
[
[
194,
24,
537
],
[
537,
24,
1511
]
],
[
[
194,
40,
1413
],
[
1413,
40,
1511
]
],
[
[
194,
35,
262
],
[
262,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Darifenacin (Compound) resembles Fexofenadine (Compound) and Fexofenadine (Compound) resembles Mepenzolate (Comp... |
DB00230 | DB00835 | 784 | 100 | [
"DDInter1516",
"DDInter245"
] | Pregabalin | Brompheniramine | Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evide... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
784,
24,
100
]
],
[
[
784,
24,
832
],
[
832,
24,
100
]
],
[
[
784,
24,
649
],
[
649,
63,
100
]
],
[
[
784,
25,
475
],
[
475,
24,... | [
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],... | Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Clofedan... |
DB00344 | DB01611 | 1,302 | 1,487 | [
"DDInter1543",
"DDInter893"
] | Protriptyline | Hydroxychloroquine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
1302,
25,
1487
]
],
[
[
1302,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
1302,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
1302,
21,
28658
],
[
... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Protriptyline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Protriptyli... |
DB08899 | DB11718 | 129 | 927 | [
"DDInter649",
"DDInter640"
] | Enzalutamide | Encorafenib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
129,
25,
927
]
],
[
[
129,
62,
112
],
[
112,
23,
927
]
],
[
[
129,
63,
1088
],
[
1088,
24,
927
]
],
[
[
129,
24,
720
],
[
720,
2... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin and ... |
DB00188 | DB05679 | 168 | 1,683 | [
"DDInter222",
"DDInter1907"
] | Bortezomib | Ustekinumab | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
168,
24,
1683
]
],
[
[
168,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
168,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
168,
63,
305
],
[
305,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib ma... |
DB00556 | DB08871 | 1,262 | 36 | [
"DDInter1429",
"DDInter666"
] | Perflutren | Eribulin | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1262,
24,
36
]
],
[
[
1262,
63,
1424
],
[
1424,
24,
36
]
],
[
[
1262,
24,
820
],
[
820,
24,
36
]
],
[
[
1262,
24,
28
],
[
28,
63... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"... | Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine m... |
DB08931 | DB09054 | 947 | 384 | [
"DDInter1600",
"DDInter905"
] | Riociguat | Idelalisib | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
947,
24,
384
]
],
[
[
947,
63,
888
],
[
888,
24,
384
]
],
[
[
947,
24,
466
],
[
466,
63,
384
]
],
[
[
947,
25,
760
],
[
760,
63,... | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
... | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Daroluta... |
DB00845 | DB08899 | 1,490 | 129 | [
"DDInter406",
"DDInter649"
] | Clofazimine | Enzalutamide | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1490,
24,
129
]
],
[
[
1490,
24,
918
],
[
918,
1,
129
]
],
[
[
1490,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1490,
21,
28703
],
[
28703,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Clofazimine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Clofazimine (Compound) causes Pruritus (Side Effect) and... |
DB00286 | DB09098 | 380 | 98 | [
"DDInter439",
"DDInter1700"
] | Conjugated estrogens | Somatrem | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
380,
24,
98
]
],
[
[
380,
24,
159
],
[
159,
63,
98
]
],
[
[
380,
24,
1573
],
[
1573,
24,
98
]
],
[
[
380,
63,
1647
],
[
1647,
24... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrect... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00099 | DB12893 | 440 | 586 | [
"DDInter735",
"DDInter1629"
] | Filgrastim | Sacituzumab govitecan | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Moderate | 1 | [
[
[
440,
24,
586
]
],
[
[
440,
24,
869
],
[
869,
24,
586
]
],
[
[
440,
63,
599
],
[
599,
24,
586
]
],
[
[
440,
25,
1064
],
[
1064,
2... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab ... |
DB08820 | DB08886 | 1,478 | 637 | [
"DDInter997",
"DDInter126"
] | Ivacaftor | Asparaginase Erwinia chrysanthemi | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
1478,
24,
637
]
],
[
[
1478,
63,
392
],
[
392,
24,
637
]
],
[
[
1478,
24,
1421
],
[
1421,
63,
637
]
],
[
[
1478,
24,
850
],
[
850,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapati... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Be... |
DB01254 | DB06802 | 1,213 | 282 | [
"DDInter484",
"DDInter1280"
] | Dasatinib | Nepafenac (ophthalmic) | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cycloox... | Moderate | 1 | [
[
[
1213,
24,
282
]
],
[
[
1213,
64,
886
],
[
886,
1,
282
]
],
[
[
1213,
63,
307
],
[
307,
1,
282
]
],
[
[
1213,
63,
1335
],
[
1335,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nepafenac"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
],
[
"Ketorolac",
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Dasatinib may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac (Compound) resembles Nepafenac (Compound)
Dasatinib may cause a moderate interaction that could exacerbate diseases when ... |
DB00001 | DB09079 | 1,578 | 1,496 | [
"DDInter1037",
"DDInter1296"
] | Lepirudin | Nintedanib | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
1578,
24,
1496
]
],
[
[
1578,
25,
707
],
[
707,
24,
1496
]
],
[
[
1578,
24,
765
],
[
765,
24,
1496
]
],
[
[
1578,
25,
235
],
[
235,
... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",... | Lepirudin may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate i... |
DB06210 | DB13749 | 72 | 1,473 | [
"DDInter631",
"DDInter1116"
] | Eltrombopag | Magnesium gluconate | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
72,
24,
1473
]
],
[
[
72,
63,
544
],
[
544,
24,
1473
]
],
[
[
72,
24,
853
],
[
853,
24,
1473
]
],
[
[
72,
24,
627
],
[
627,
25,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfat... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken w... |
DB06616 | DB09083 | 594 | 880 | [
"DDInter224",
"DDInter996"
] | Bosutinib | Ivabradine | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
594,
25,
880
]
],
[
[
594,
63,
480
],
[
480,
24,
880
]
],
[
[
594,
24,
1478
],
[
1478,
24,
880
]
],
[
[
594,
24,
159
],
[
159,
6... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor... |
DB00208 | DB00969 | 1,018 | 2 | [
"DDInter1804",
"DDInter52"
] | Ticlopidine | Alosetron | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Moderate | 1 | [
[
[
1018,
24,
2
]
],
[
[
1018,
6,
6017
],
[
6017,
45,
2
]
],
[
[
1018,
21,
29058
],
[
29058,
60,
2
]
],
[
[
1018,
24,
1416
],
[
1416,
... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)"... | Ticlopidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Alosetron (Compound)
Ticlopidine (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Alosetron (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib and Rofe... |
DB00794 | DB04837 | 759 | 649 | [
"DDInter1521",
"DDInter407"
] | Primidone | Clofedanol | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
759,
24,
649
]
],
[
[
759,
24,
1376
],
[
1376,
24,
649
]
],
[
[
759,
63,
832
],
[
832,
40,
649
]
],
[
[
759,
63,
701
],
[
701,
2... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamin... |
DB00352 | DB15965 | 482 | 1,330 | [
"DDInter1814",
"DDInter1270"
] | Tioguanine | Naxitamab | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
482,
24,
1330
]
],
[
[
482,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
482,
25,
770
],
[
770,
24,
1330
]
],
[
[
482,
63,
168
],
[
168,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tioguanine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause... |
DB01166 | DB06663 | 477 | 1,154 | [
"DDInter379",
"DDInter1398"
] | Cilostazol | Pasireotide | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
477,
25,
1154
]
],
[
[
477,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
477,
62,
112
],
[
112,
23,
1154
]
],
[
[
477,
63,
62
],
[
62,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Cilostazol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused b... | Cilostazol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken... |
DB00420 | DB00572 | 508 | 85 | [
"DDInter1532",
"DDInter136"
] | Promazine | Atropine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Moderate | 1 | [
[
[
508,
24,
85
]
],
[
[
508,
24,
19
],
[
19,
24,
85
]
],
[
[
508,
25,
1166
],
[
1166,
40,
85
]
],
[
[
508,
24,
1133
],
[
1133,
40,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Promazine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron (Compound) r... |
DB00065 | DB08886 | 581 | 637 | [
"DDInter923",
"DDInter126"
] | Infliximab | Asparaginase Erwinia chrysanthemi | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
581,
24,
637
]
],
[
[
581,
63,
491
],
[
491,
24,
637
]
],
[
[
581,
25,
250
],
[
250,
63,
637
]
],
[
[
581,
25,
167
],
[
167,
24,... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegi... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Infliximab may lead to a major life threatening interaction when ta... |
DB06674 | DB12240 | 908 | 110 | [
"DDInter837",
"DDInter1485"
] | Golimumab | Polatuzumab vedotin | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Major | 2 | [
[
[
908,
25,
110
]
],
[
[
908,
63,
467
],
[
467,
24,
110
]
],
[
[
908,
64,
1419
],
[
1419,
24,
110
]
],
[
[
908,
24,
1593
],
[
1593,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Si... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Golimumab may lead to a major life threatening interaction when taken with Imatinib and Imatinib may c... |
DB00906 | DB01142 | 1,567 | 1,264 | [
"DDInter1801",
"DDInter593"
] | Tiagabine | Doxepin | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1567,
24,
1264
]
],
[
[
1567,
24,
401
],
[
401,
24,
1264
]
],
[
[
1567,
63,
832
],
[
832,
24,
1264
]
],
[
[
1567,
24,
649
],
[
649,
... | [
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tri... |
DB00584 | DB01225 | 610 | 500 | [
"DDInter638",
"DDInter645"
] | Enalapril | Enoxaparin | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
610,
24,
500
]
],
[
[
610,
21,
28778
],
[
28778,
60,
500
]
],
[
[
610,
1,
664
],
[
664,
24,
500
]
],
[
[
610,
40,
743
],
[
743,
... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side... | Enalapril (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Enoxaparin (Compound)
Enalapril (Compound) resembles Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Enalapril (Compound) resem... |
DB01238 | DB11827 | 673 | 433 | [
"DDInter118",
"DDInter669"
] | Aripiprazole | Ertugliflozin | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
673,
24,
433
]
],
[
[
673,
63,
959
],
[
959,
24,
433
]
],
[
[
673,
24,
820
],
[
820,
24,
433
]
],
[
[
673,
40,
1630
],
[
1630,
2... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and ... |
DB00493 | DB01172 | 1,087 | 416 | [
"DDInter323",
"DDInter1004"
] | Cefotaxime | Kanamycin | Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under var... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
1087,
24,
416
]
],
[
[
1087,
21,
28680
],
[
28680,
60,
416
]
],
[
[
1087,
1,
164
],
[
164,
24,
416
]
],
[
[
1087,
40,
1024
],
[
1024,
... | [
[
[
"Cefotaxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Cefotaxime",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (... | Cefotaxime (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Kanamycin (Compound)
Cefotaxime (Compound) resembles Cefalotin (Compound) and Cefalotin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Cefotaxime (Compound) resembles Cefpodoxime (Compound) and... |
DB00188 | DB01004 | 168 | 563 | [
"DDInter222",
"DDInter806"
] | Bortezomib | Ganciclovir | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
168,
24,
563
]
],
[
[
168,
24,
248
],
[
248,
40,
563
]
],
[
[
168,
7,
17515
],
[
17515,
46,
563
]
],
[
[
168,
18,
17695
],
[
17695,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Bortezomib (Compound) upregulates DHDDS (Gene) and DHDDS (Gene) is upregulated by Ganciclovir (Compound)
Bortezomib (Compound) downregulates CANT1 (Gen... |
DB01042 | DB09074 | 1,307 | 1,362 | [
"DDInter1144",
"DDInter1327"
] | Melphalan | Olaparib | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1307,
24,
1362
]
],
[
[
1307,
63,
896
],
[
896,
24,
1362
]
],
[
[
1307,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
1307,
24,
385
],
[
385,
... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"... | Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab... |
DB00398 | DB09268 | 79 | 1,662 | [
"DDInter1702",
"DDInter1464"
] | Sorafenib | Picosulfuric acid | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
79,
24,
1662
]
],
[
[
79,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
79,
24,
1164
],
[
1164,
24,
1662
]
],
[
[
79,
24,
484
],
[
484,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipr... |
DB00938 | DB01579 | 455 | 341 | [
"DDInter1635",
"DDInter1439"
] | Salmeterol | Phendimetrazine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
455,
24,
341
]
],
[
[
455,
21,
28662
],
[
28662,
60,
341
]
],
[
[
455,
24,
959
],
[
959,
24,
341
]
],
[
[
455,
24,
1281
],
[
1281,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salmeterol",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is cause... | Salmeterol (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Phendimetrazine (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Phendimetr... |
DB01056 | DB08826 | 571 | 1,292 | [
"DDInter1823",
"DDInter489"
] | Tocainide | Deferiprone | An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
571,
25,
1292
]
],
[
[
571,
24,
4
],
[
4,
25,
1292
]
],
[
[
571,
64,
1064
],
[
1064,
25,
1292
]
],
[
[
571,
63,
599
],
[
599,
25... | [
[
[
"Tocainide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Tocainide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
... | Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Deferiprone
Tocainide may lead to a major life threatening interaction when taken with Cladribine and Cladrib... |
DB01240 | DB06822 | 885 | 802 | [
"DDInter657",
"DDInter1812"
] | Epoprostenol | Tinzaparin | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Major | 2 | [
[
[
885,
25,
802
]
],
[
[
885,
23,
944
],
[
944,
62,
802
]
],
[
[
885,
63,
222
],
[
222,
24,
802
]
],
[
[
885,
24,
1427
],
[
1427,
6... | [
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile... | Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutra... |
DB01064 | DB01170 | 1,148 | 1,150 | [
"DDInter987",
"DDInter846"
] | Isoprenaline | Guanethidine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
1148,
24,
1150
]
],
[
[
1148,
63,
1445
],
[
1445,
24,
1150
]
],
[
[
1148,
24,
1344
],
[
1344,
63,
1150
]
],
[
[
1148,
23,
617
],
[
617... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Canag... |
DB00443 | DB09037 | 251 | 920 | [
"DDInter195",
"DDInter1413"
] | Betamethasone | Pembrolizumab | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and ... | Moderate | 1 | [
[
[
251,
24,
920
]
],
[
[
251,
1,
891
],
[
891,
24,
920
]
],
[
[
251,
40,
167
],
[
167,
24,
920
]
],
[
[
251,
25,
770
],
[
770,
25,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may ca... | Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when t... |
DB00601 | DB00773 | 453 | 896 | [
"DDInter1073",
"DDInter702"
] | Linezolid | Etoposide | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
453,
24,
896
]
],
[
[
453,
7,
7669
],
[
7669,
46,
896
]
],
[
[
453,
18,
7095
],
[
7095,
46,
896
]
],
[
[
453,
21,
28864
],
[
28864,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Linezolid",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Comp... | Linezolid (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Etoposide (Compound)
Linezolid (Compound) downregulates CCL2 (Gene) and CCL2 (Gene) is upregulated by Etoposide (Compound)
Linezolid (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Eto... |
DB00599 | DB01041 | 682 | 770 | [
"DDInter1795",
"DDInter1789"
] | Thiopental | Thalidomide | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
682,
24,
770
]
],
[
[
682,
6,
6365
],
[
6365,
45,
770
]
],
[
[
682,
24,
849
],
[
849,
63,
770
]
],
[
[
682,
63,
1614
],
[
1614,
... | [
[
[
"Thiopental",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Thiopental",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)"... | Thiopental (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Thalidomide (Compound)
Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Thiopental may c... |
DB08822 | DB09112 | 911 | 1,455 | [
"DDInter156",
"DDInter1306"
] | Azilsartan medoxomil | Nitrous acid | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
911,
24,
1455
]
],
[
[
911,
40,
217
],
[
217,
24,
1455
]
],
[
[
911,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
911,
63,
885
],
[
885,
... | [
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Azilsartan medoxomil",
"{u} (Compound) resembles {v} (Compound)",
"Olmesartan"
],
[
"Olmesartan",
"{... | Azilsartan medoxomil (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a mod... |
DB00586 | DB06700 | 1,512 | 643 | [
"DDInter537",
"DDInter511"
] | Diclofenac | Desvenlafaxine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
1512,
24,
643
]
],
[
[
1512,
63,
1100
],
[
1100,
1,
643
]
],
[
[
1512,
6,
8374
],
[
8374,
45,
643
]
],
[
[
1512,
21,
28709
],
[
28709,... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Diclofenac (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Desvenlafaxine (Compound)
Diclofenac (Compound) causes Decreased appetite (Side Ef... |
DB10315 | DB11703 | 1,137 | 405 | [
"DDInter1127",
"DDInter9"
] | Measles virus vaccine live attenuated | Acalabrutinib | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1137,
25,
405
]
],
[
[
1137,
64,
58
],
[
58,
24,
405
]
],
[
[
1137,
25,
1619
],
[
1619,
63,
405
]
],
[
[
1137,
64,
384
],
[
384,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken w... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.